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Abstract: Identification and quantitative monitoring of mutant BCR-ABL1 subclones displaying
resistance to tyrosine kinase inhibitors (TKIs) have become important tasks in patients with
Ph-positive leukemias. Different technologies have been established for patient screening. Various
next-generation sequencing (NGS) platforms facilitating sensitive detection and quantitative
monitoring of mutations in the ABL1-kinase domain (KD) have been introduced recently, and are
expected to become the preferred technology in the future. However, broad clinical implementation
of NGS methods has been hampered by the limited accessibility at different centers and the current
costs of analysis which may not be regarded as readily affordable for routine diagnostic monitoring.
It is therefore of interest to determine whether NGS platforms can be adequately substituted by other
methodological approaches. We have tested three different techniques including pyrosequencing,
LD (ligation-dependent)-PCR and NGS in a series of peripheral blood specimens from chronic
myeloid leukemia (CML) patients carrying single or multiple mutations in the BCR-ABL1 KD.
The proliferation kinetics of mutant subclones in serial specimens obtained during the course of
TKI-treatment revealed similar profiles via all technical approaches, but individual specimens showed
statistically significant differences between NGS and the other methods tested. The observations
indicate that different approaches to detection and quantification of mutant subclones may be
applicable for the monitoring of clonal kinetics, but careful calibration of each method is required for
accurate size assessment of mutant subclones at individual time points.
Keywords: BCR-ABL1; CML; quantitative analysis of mutant subclones; NGS; LD-PCR;
pyrosequencing
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1. Introduction
The clinical implementation of tyrosine kinase inhibitors (TKIs) over a decade ago has
revolutionized treatment of chronic myeloid leukemia (CML) but the occurrence of resistance, most
commonly attributable to point mutations in the tyrosine kinase domain (TKD) of the BCR-ABL1
fusion gene, remains an important challenge [1–5]. Timely identification of mutations associated
with TKI resistance is therefore of great relevance for the clinical management of CML patients, and
specific recommendations for mutational screening are provided by the European Leukemia Net (ELN)
and the National Comprehensive Cancer Network (NCCN) [6–8]. The currently recommended and
most commonly used technique for the detection of mutations is bidirectional Sanger sequencing of
PCR-amplified BCR-ABL1 fragments encompassing the entire TKD [6,7,9,10]. Due to its detection limit
in the range of 10%–20%, this technique only facilitates assessment of relatively large mutant subclones,
and permits only rough estimation of their size [6,7,9,10]. Since the detection of a mutation does not
necessarily imply imminent onset of resistant disease [11–13], monitoring of the proliferation kinetics
of mutant subclones during TKI treatment can provide more relevant clinical information [14,15].
In order to permit early detection of mutations, and to assess the biological behavior of mutant
subclones during therapy, a number of sensitive methods facilitating quantitative monitoring have
been developed with the aim to establish a basis for timely and rational clinical decisions [15–19].
Although serial measurement of BCR-ABL1 levels by reverse-transcription real-time quantitative PCR
remains the mainstay of patient surveillance during treatment [7], we have recently reported that
the expansion of mutant subclones can be observed even prior to detection of rising fusion gene
transcripts [15]. These observations underline the potential of sensitive and quantitative mutational
analyses to provide early information on impending resistant disease. A variety of methodological
approaches to detection and quantitative monitoring of mutant BCR-ABL1 subclones have been
published over the past few years, including allele-specific real-time PCR [20], pyrosequencing [12,18],
ligation-dependent PCR techniques (LD-PCR; L-PCR) [19,21], methods based on various other
principles [22–26], and, most recently, next-generation sequencing (NGS)-based methods exploiting
different technical platforms [14,16,17,27]. The indicated methods are superior to Sanger sequencing in
terms of sensitivity and ability to determine the size of mutant subclones. However, they display major
differences with respect to relevant parameters, including the detection limit (ranging from 0.05%
to 5%), the accuracy of quantitative analysis (if reported), and the clinical applicability with regard
to technical prerequisites and overall costs. The NGS platforms offer many advantages over other
approaches to detection and quantitative monitoring of mutant BCR-ABL1 subclones [14,16,17,27], and
will likely become the leading technology for this and other clinically relevant applications. However,
the present costs of analysis and the limited accessibility of appropriate diagnostic services hamper their
clinical implementation at many centers, thus emphasizing the current need for alternative techniques.
We have therefore selected two well-established methods displaying detection limits in a range similar
to NGS (ě1%) including pyrosequencing [18] and LD-PCR [19], and compared their performance
in quantitative analysis of mutant BCR-ABL1 subclones to next generation sequencing on the MiSeq
(Illumina, San Diego, CA, USA) or GS junior/FLX+ (Roche, Basel, Switzerland) platforms. We have
analyzed individual and serial peripheral blood specimens from CML patients harboring single or
multiple point mutations in the BCR-ABL1 TKD, and demonstrate that the methods tested show similar
results with regard to the assessment of subclone kinetics. However, the differences observed between
measurements of clonal size at individual time points highlight the need for appropriate calibration of
any technical approach employed.
2. Results
Of 105 cDNA samples derived from peripheral blood of CML patients carrying point mutations
in the BCR-ABL1 TKD, 46 specimens including both individual and serial samples passed the initial
quality control, and could therefore be subjected to quantitative comparison of subclone size assessment
by different technical approaches. This limitation indicated that storage of clinical specimens under
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suboptimal conditions can be a major impediment for ensuing molecular analyses requiring high
quality of RNA/cDNA. The parameters of quantitative analysis by the LD-PCR method including
accuracy, reproducibility, and limit of detection had been previously established and characterized at
our center, and provided a basis for the measurements performed. The analyses were based on the
investigation of specimens obtained from different clinical centers and comprised two independent data
sets, one including the pairwise and comprehensive comparison between LD-PCR, pyrosequencing
and NGS on the MiSeq (Illumina) platform, and the other the comparison of LD-PCR with NGS on the
GS Junior (Roche) platform. The absolute quantitative values obtained by the different methods are
displayed in Tables 1 and 2. The specimens analyzed within both data sets displayed nine different
mutations including p.M244V, p.G250E, p.Q252H (c.756 G>T), p.Y253H, p.E255K, p.V299L (c.895 G>T),
p.T315I, p.M351T, and p.F359V. Individual patients revealed up to three mutant subclones but none of
them were present in compound constellations, as determined by NGS. Results of the first dataset are
illustrated by Bland-Altmann plots showing the differences in measurement against the average of all
pairwise-compared methods tested (Figure 1a–c). The comparison of differences between LD-PCR and
pyrosequencing (∆1) revealed virtually all data points within the 95% confidence interval (CI), with
a single exception, and indicated a trend towards slightly higher values determined by the LD-PCR
method (Figure 1a). Comparison of LD-PCR and NGS on the MiSeq platform (∆2) showed only
two values outside the 95% CI, but displayed greater divergence between paired sample analyses
than LD-PCR and pyrosequencing (Figure 1b). A more pronounced disparity was observed in the
comparison of differences between pyrosequencing and NGS on the MiSeq platform (∆3) but all data
points, with a single exception, were still within the 95% CI (Figure 1c). Analysis of the second dataset
based on a different series of cDNA specimens, permitting only comparison of LD-PCR with NGS
on the GS junior platform, revealed the most concordant results with a narrow range of the 95% CI
(Figure 1d).
Table 1. Single and serial peripheral blood specimens from 19 CML patients displaying up to three
different mutant subclones were subjected to quantitative analysis by LD-PCR, pyrosequencing and/or
NGS on the MiSeq platform (Illumina). Serially derived specimens from individual patients are
indicated by increasing numbers after the hyphen. The BCR-ABL1 transcript levels in individual
specimens are indicated according to the International Scale (IS). The sizes of mutant subclones
determined by the technical approaches tested are displayed as a percentage of the BCR-ABL1 positive
cells. n.a., not analyzed; n.d., not detected; pos, detected but not quantified.
Sample Number BCR-ABL1 % (IS) Mutation LD-PCR (% Mut) Pyroseq (% Mut) NGS MiSeq (% Mut)
1-1 0.670 p.E255K 97 84 92
1-2 1.700 p.E255K 100 86 96
2-1 9.834 p.E255K 82 pos n.a.
2-2 0.667 p.E255K 97 84 92
2-3 2.338 p.E255K 97 86 n.a.
3-1 1.670 p.E255K 41 pos 28
3-2 4.180 p.E255K 49 pos 22
3-3 5.800 p.E255K 61 pos 35
3-1 1.670 p.Y253F 27 pos 20
3-2 4.180 p.Y253F 27 pos 14
3-3 5.800 p.Y253F 7 pos 5
3-1 1.670 p.T315I 6 pos 8
3-2 4.180 p.T315I 9 pos 20
3-3 5.800 p.T315I 3 pos n.a.
4-1 20.015 p.T315I 92 89 n.a.
4-2 15.692 p.T315I 56 50 n.a.
4-3 13.075 p.T315I 62 54 n.a.
5-1 18.550 p.V299L 100 96 91
5-2 1.380 p.V299L 49 39 19
5-3 20.670 p.V299L 0 0 2
5-1 18.550 p.T315I 2 0 0
5-2 1.380 p.T315I 54 54 75
5-3 20.670 p.T315I 100 97 91
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Table 1. Cont.
Sample Number BCR-ABL1 % (IS) Mutation LD-PCR (% Mut) Pyroseq (% Mut) NGS MiSeq (% Mut)
6-1 41.355 p.F359V 10 8 n.a.
6-2 29.897 p.F359V 51 60 n.a.
6-3 10.786 p.F359V 12 16 n.a.
6-4 11.302 p.F359V 0 0 n.a.
7-1 0.080 p.F359V n.a. n.a. 67
7-2 0.050 p.F359V 88 80 35
7-3 0.120 p.F359V 17 24 13
8 6.280 p.G250E n.d. pos 0
9 20.060 p.T315I 98 89 77
9 20.060 p.G250E n.a. n.a. 33
10-1 0.108 p.Q252H 67 64 n.a.
10-2 0.200 p.Q252H 72 72 n.a.
10-3 0.079 p.Q252H 46 n.a. 61
10-4 0.016 p.Q252H 1 n.a. n.a.
10-5 0.020 p.Q252H 10 10 n.a.
11 1.990 p.M244V 90 pos 80
12 2.670 p.T315I 97 96 93
13 35.570 p.E255K 94 62 47
14 8.640 p.M244V 77 72 73
14 8.640 p.Y253H 9 10 7
15-1 18.218 p.T315I 0 0 n.a.
15-2 21.540 p.T315I 0 0 n.a.
15-3 15.313 p.T315I 37 45 44
16 18.500 p.Y253H 98 95 94
17 14.370 p.T315I 34 41 40
18 0.040 p.Y253H n.a. 40 36
19 0.160 p.T315I 100 97 97
Table 2. Displayed are serial specimens from three CML patients, each carrying two or more different
mutant subclones, which were analyzed by LD-PCR and NGS on the GS junior platform (Roche). n.a.,
not analyzed.
Sample Number BCR-ABL1 % (IS) Mutation LD-PCR (% Mut) NGS GS Junior (% Mut)
1-1 7.200 p.M351T 86 72
1-2 0.180 p.M351T n.a. 26
1-1 7.200 p.G250E 5 5
1-2 0.180 p.G250E 1 0
2-1 5.900 p.T315I 26 26
2-2 15.000 p.T315I 66 69
2-1 5.900 p.M351T 1 6
2-2 15.000 p.M351T 1 0
2-1 5.900 p.Y253H 3 0
2-2 15.000 p.Y253H 6 17
3-1 0.140 p.M351T 48 59
3-2 2.300 p.M351T 16 9
3-3 8.400 p.M351T 1 0
3-1 0.140 p.F359V 35 30
3-2 2.300 p.F359V 4 5
3-3 8.400 p.F359V 0 2
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identical results of different measurements. 
The distribution of differences including ∆1 (LD-PCR versus pyrosequencing) and ∆2 (LD-PCR 
versus NGS-MiSeq platform) is illustrated by histograms and corresponding density estimates 
(Figure 2). The central tendency of ∆2 is slightly larger than that of ∆1, but the difference is not 
statistically significant (Table 3). The much wider spread observed in ∆2 compared to ∆1 indicates a 
greater similarity between results obtained by LD-PCR and pyrosequencing than between LD-PCR 
and NGS on the MiSeq platform, which is highly significant according to a folded F Test (p = 0.0001). 
The smallest differences between quantitative measurements were seen in the comparison of 
LD-PCR with NGS on the GS Junior platform using a small set of samples (n: 15, mean ∆ value: 
−0.074, Standard Deviation (SD): 6.3). However, due to the different set of cDNA specimens 
employed for this test series, statistical analysis correlating the data to the pairwise comparisons 
performed within the other test series was not possible (see Table 2 for quantitative results). 
In addition to the comparison of quantitative measurements in individual specimens, the 
availability of serial samples from nine patients permitted the assessment of proliferation kinetics of 
mutant subclones by different techniques. Two examples comparing quantitative monitoring of 
mutant subclones in consecutive specimens by LD-PCR, pyrosequencing and NGS are displayed in 
Figure 3. The concordant kinetics documents the similarity of results generated by the three methods 
with regard to the dynamics of subclone evolution. 
Figure 1. Comparison of quantitative mutant subclone assessment by different methods.
The Bland-Altmann plots displayed show the distribution of mean ∆ values (∆M) with the
respective 95% confidence intervals (dashed lines) for the pairwise comparison of (a) LD-PCR versus
pyrosequencing-∆1; (b) LD-PCR versus NGS (MiSeq platform)-∆2; (c) pyrosequencing versus NGS
( iSeq platform)-∆3; (d) LD-PCR versus NGS (GS Junior platform). The number of data points varies
between different pairwise co parative analyses because a proportion of cDNA speci ens were not
a enable to testing by all technical approaches. In some instances, individual points represent identical
results of different measurements.
The distribution of differences including ∆1 (LD-PCR versus pyrosequencing) and ∆2 (LD-PCR
versus NGS-MiSeq platform) is illustrated by histograms and corresponding density estimates
(Figure 2). The central tendency of ∆2 is slightly larger than that of ∆1, but the difference is not
statistically significant (Table 3). The much wider spread observed in ∆2 compared to ∆1 indicates a
greater similarity between results obtained by LD-PCR and pyrosequencing than between LD-PCR
and NGS on the MiSeq platform, which is highly significant according to a folded F Test (p = 0.0001).
Table 3. Comparison of quantitative mutant subclone assessment using different methods. Overview
of results obtained by pairwise comparison of measurements by LD-PCR, pyrosequencing, and NGS
on the Miseq platform (based on quantitative values displayed in Table 1). The number of samples
a enable to comparison by different methods varies because a proportion of cDNA specimens were not
large enough for analysis by ll technical approaches. The mean values are not significantly different
ccording to statistical analyses performed by th two sampl T-T t (p = 0.17) or th more refi d
ANOVA test based on repeated meas rements (p = 0.11), indicating that none of the methods has
an obvious bias towards larger or smaller values. However, the SD of ∆2 (16.1) in comparison to ∆1
(7.8) is significantly higher ac or ing to the fold d F-Test (p < 0.0001), indicating the most pronounc d
differences in test results obtained by LD-PCR and NGS (Miseq).
Specifications LD-PCR/Pyrosequencing LD-PCR/NGS Pyrosequencing/NGS
Number of samples
compared (N) 33 30 21
Difference of mean
values (∆M) 3.5 8 3.6
Standard deviation (SD) 7.8 16.1 13.1
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of results obtained by pairwise comparison of measurements by LD-PCR, pyrosequencing, and NGS 
on the Miseq platform (based on quantitative values displayed in Table 1). The number of samples 
amenable to comparison by different methods varies because a proportion of cDNA specimens were 
not large enough for analysis by all technical approaches. The mean values are not significantly 
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has an obvious bias towards larger or smaller values. However, the SD of ∆2 (16.1) in comparison to 
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Specifications LD-PCR/Pyrosequencing LD-PCR/NGS Pyrosequencing/NGS
Number of samples compared (N) 33 30 21 
Difference of mean values (∆M) 3.5 8 3.6 
Standard deviation (SD) 7.8 16.1 13.1 
  
Figure 2. Distribution of ∆M values. Histograms and corresponding density estimators for the
differences between methods are displayed. The upper panel represents ∆1, the difference between
LD-PCR and pyrosequencing, and the bottom panel reflects ∆2, the difference between LD-PCR and
NGS on the Miseq platform. The values determined by LD-PCR and pyrosequencing showed greater
similarity than those obtained by LD-PCR and Miseq-NGS. The normal density (blue line) clearly
shows greater variance for ∆2 in comparison to ∆1.
The smallest differences between quantitative measurements were seen in the comparison of
LD-PCR with NGS on the GS Junior platform using a small set of samples (n: 15, mean ∆ value: ´0.074,
Standard Deviation (SD): 6.3). However, due to the different set of cDNA specimens employed for this
test series, statistical analysis corre ating the data to the pairwise comparisons performed within the
other test seri s was not possible (s e Table 2 for quantitative results).
In addition to the comparison of quantitative measurements in individual specimens, the
availability of serial samples from nine patients permitted the assessment of proliferation kinetics
of mutant subclones by different techniques. Two examples comparing quantitative monitoring of
mutant subclones in consecutive specimens by LD-PCR, pyrosequencing and NGS are displayed in
Figure 3. The concordant kinetics documents the similarity of results generated by the three methods
with regard to the dynamics of subclone evolution.
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particularly by the largely overlapping curves of analyses by LD-PCR and pyrosequencing. 
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3. Discussion
Detection of mutations in the BCR-ABL1 TKD has become an important parameter for the
management of patients with Ph-positive leukemias [15,16,28,29], and monitoring of the size of
mutant subclones indicative of their sensitivity or resistance to treatment can be expected to take
on more clinical importance in the foreseeable future. Although a variety of techniques greatly
expanding the information provided by Sanger sequencing were introduced [14,16–21,27], studies
on direct comparison of different quantitative approaches have been lacking. Clinically relevant
detection levels for mutant subclones have not been determined to date, indicating that the monitoring
of kinetics may be a more informative parameter. The accuracy of quantitative measurement of
mutant subclones as well as the sensitivity of detection could be of importance for adequate patient
surveillance. Improvement of the detection limit offered by Sanger sequencing in conjunction with
the ability to accurately quantify mutant subclones has therefore been the main challenge for all new
technical approaches. Various NGS platforms meeting this requirement have been recently introduced,
and their important advantages include the ability to screen the entire TKD for the presence of single
and multiple mutations, to identify polyclonal and compound constellations in the presence of more
than one mutation, and to determine the relative sizes of all mutations present at individual time
points [14,16,17,27]. Some NGS techniques were shown to facilitate coverage of the complete BCR-ABL1
TKD and even adjacent sequences of potential clinical relevance in a single long read, thus permitting
more economic identification of compound mutations [14,27]. However, the practical detection
limit of NGS analyses seems to be in the range of 1% [14,16,17,27], when searching for unknown
mutations, due to the need to reliably exclude mutational artifacts by implementing appropriate
bioinformatic algorithms. We have therefore selected methods providing a similar detection limit,
including LD-PCR and pyrosequencing [18,19], for the comparison of performance with regard to size
assessment of mutant subclones. Other technical approaches such as RT-qPCR [20,25] or digital PCR
(Bio-Rad, Hercules, CA, USA) certainly represent additional alternative options, provided that the
mutations to be monitored are known. The number of specimens available for comparative analyses
was restricted by the stringent quality criteria and the required amount of material. This limitation
resulted in variable sample numbers for the pairwise comparison of the methods tested, thus requiring
appropriate statistical analysis for the evaluation of all measurements. Comparison of the data
generated by LD-PCR, pyrosequencing and NGS on the Miseq platform revealed concordant kinetics,
but individual values were similar between the former two methodologies, and showed significant
differences to the values determined by NGS. Since the LD-PCR technique was precisely calibrated for
accurate quantitative analysis [19], the differences observed should raise the awareness of the need to
carefully calibrate NGS-based approaches for size assessment of mutant subclones.
The highest level of concordance was observed in the comparison of LD-PCR and NGS on the GS
junior platform, but the smaller number of samples analyzed and the use of a different set of cDNA
specimens for this test series must be considered. The different NGS approaches involved could not
be systematically compared due to the limited amount of available specimens. Nevertheless, data
generated on different NGS platforms were obtained in two instances. The anecdotal observations
revealed differences between individual NGS platforms similar to those detected between the other
methods tested, possibly suggesting a good level of concordance but no uniformity of results provided
by different NGS approaches.
4. Experimental Section
4.1. Material
Patient Material and Ethical Statement
Archived cDNA specimens from CML patients previously identified to display mutations in the
BCR-ABL1 TKD were obtained from different clinical centers including the Institute of Hematology
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and Blood Transfusion, Prague, Czech Republic; the Hematology Department, Jagiellonian University,
Krakow, Poland, the Section for Hematology, Department of Medicine, University Hospital of Lund,
Sweden and the Hammersmith Hospital, London, UK (Ethical approval, REC reference: 06/Q0406/47).
In the present study, a total of 105 specimens were tested by different technical approaches to mutational
analysis. The specimens analyzed included exclusively archived residual cDNA from patients who had
previously undergone molecular mutational analysis with informed consent at the centers involved.
Initial control of the amount and quality of cDNA was performed by photometric measurement
and PCR amplification of the ABL1 gene [30]. Forty six samples revealing ABL1 copy numbersě1 ˆ 104
per reaction were deemed eligible for quantitative analysis of mutant subclones.
4.2. Methods
Quantitative Analysis of Mutant BCR-ABL1 Subclones
Eligible cDNA samples were investigated using different technical approaches to quantitative
mutational analysis including LD-PCR, pyrosequencing and NGS [14,17–19,31]. The principle of
LD-PCR relies on competitive hybridization of wildtype (WT) or mutation-specific oligonucleotide
probes followed by PCR amplification and assessment of the PCR products by fragment length
analysis on a sequencing machine. Technical details of LD-PCR have been described previously [19].
Pyrosequencing is based on sequence analysis by nucleotide chain synthesis, thus also permitting
quantitative detection of multi-allelic mutations, which is not possible by the LD-PCR technique.
Technical details of the pyrosequencing method have been described earlier [18]. Both methods
facilitate size assessment of point-mutated subclones with a limit of detection in the range of 1%–5%.
However, prior knowledge of the mutation to be analyzed is required, thus rendering these techniques
inappropriate for screening purposes. By contrast, NGS permits both screening for unknown mutations
with a detection limit of 1%, and quantitative analysis of individual or multiple mutations in a single
reaction [17,31]. Recently established NGS technologies enable also the detection and quantification
of multiple mutations within the same DNA molecule (compound mutations) by providing long
reads covering the entire sequence of interest. Technical details of the long-range NGS approach
employed were recently published [27]. The experimental design of the present study was based
primarily on the LD-PCR method, for which all validation parameters of quantitative analysis are
well documented [19]. Pairwise comparison of LD-PCR to pyrosequencing and NGS on two different
platforms was performed on the basis of individual and serial clinical specimens from CML patients
carrying mutant BCR-ABL1 subclones. Table 4 shows a comparison of important parameters for all
three technologies.
Table 4. Performance features of the methods compared.
Performance Features LD-PCR Pyrosequencing NGS
Quantitative analysis of mutant subclones yes yes yes
Prior knowledge of mutation required yes yes no
Detection of multiple mutations in one reaction no yes yes
Detection limit for mutant subclones 1%–5% 5% 1%
Accuracy of quantification ˘5% n.a. n.a.
n.a., not available.
4.3. Statistical Analysis
Bland-Altman plots including mean values and 95% confidence intervals (CI) for differences
between methods were used to determine the pairwise agreement between LD-PCR versus
pyrosequencing (∆1), LD-PCR versus NGS on the Miseq platform (∆2), pyrosequencing versus NGS on
the Miseq platform (∆3), and LD-PCR versus NGS on the GS Junior platform based on a different set
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of samples. Different statistical tests were performed to compare the disagreement of measurements
with a focus on ∆1 and ∆2. A folded F-Test (SAS PROC TTEST) was performed to test the equality of
variance between ∆1 and ∆2. Furthermore, a repeated-measures test ANOVA (SAS PROC MIXED)
was employed to assess the equality of mean values between ∆1 and ∆2. Histograms with kernel
densities are provided to illustrate the results (Figure 2).
5. Conclusions
The findings presented indicate that different methods facilitating sensitive detection of mutant
subclones and quantitative assessment of their size, such as LD-PCR or pyrosequencing, can be
regarded as eligible for clinical monitoring in terms of mutant subclone kinetics. However, the
differences between the methods tested with regard to quantitative measurement of subclone size at
individual time points highlight the need for appropriate calibration. Although NGS techniques will
likely become the methods of choice for this application due to the important advantages outlined
above, alternative techniques will be required as long as the costs of analysis and accessibility of
appropriate diagnostic services prevents broad clinical application of this technology. However, the
limitations in terms of the comparability of results generated by different methods must be taken into
consideration. Depending on the local expertise and availability of laboratory equipment, different
methods may permit adequate surveillance of BCR-ABL1 TKD mutations relevant in the context of
TKI resistance as a basis for optimal management of patients with Ph-positive leukemias.
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